Alturas Minerals Corp

Altimmune's stock crashed over 60% after its Phase 2b IMPACT trial of pemvidutide for MASH showed mixed results, with strong MASH resolution but insufficient fibrosis improvement.

D&D Pharmatech's DD01 achieved 75.8% of patients with at least 30% liver fat reduction in just 12 weeks, matching Boehringer Ingelheim's servodutide results that required 48 weeks of treatment.

Altimmune has secured a $100 million credit facility from Hercules Capital, with $15 million funded immediately and additional tranches available upon meeting clinical and financial milestones.

Boehringer Ingelheim has secured global commercialization rights for treatments co-developed with Tessellate Bio targeting tumors dependent on alternative lengthening of telomeres (ALT), present in 10-15% of all cancers.

• Altimmune announced plans to initiate Phase II trials of its GLP-1/glucagon agonist pemvidutide for alcohol use disorder in Q2 2025 and alcohol-related liver disease in Q3, expanding beyond obesity treatment. • The company's strategic expansion leverages pemvidutide's mechanism of action and the established connection between alcohol use and obesity in exacerbating liver damage. • Pemvidutide previously demonstrated 15.6% weight loss at its highest dose in the Phase II MOMENTUM obesity trial, with approximately 80% of weight loss coming from fat rather than lean muscle mass.

Altimmune's intranasal COVID-19 vaccine AdCOVID showed insufficient immune response in Phase 1 trials, leading to the termination of the development program.

Altimmune's pemvidutide, currently in Phase II trials for obesity and metabolic dysfunction-associated steatohepatitis, is projected to reach $1.21 billion in sales by 2030.

Altimmune and MindMed were added to the Nasdaq Biotechnology Index (NBI) on December 23, 2024, signaling recognition of their progress and potential.

• Long-term analysis of omaveloxolone demonstrates a favorable safety profile for treating Friedreich ataxia, with most adverse events being manageable. • The most common treatment-emergent adverse events (TEAEs) include gastrointestinal issues and elevated aminotransferase levels, typically occurring within the first 12 weeks. • Gradual dose titration of omaveloxolone over several months helps manage metabolic effects, allowing most patients to reach the full dose without significant complications. • Omaveloxolone, approved in early 2023, remains the first and only FDA-approved treatment for Friedreich ataxia, impacting approximately 1 in 40,000 people globally.

• Semaglutide 2.4 mg demonstrated statistically significant improvements in liver fibrosis and resolution of steatohepatitis in MASH patients compared to placebo. • The ESSENCE trial met its primary endpoints, showing semaglutide's potential to slow MASH progression and reverse existing liver damage. • Secondary endpoints revealed improvements in liver enzymes (ALT, AST, GGT) and the Enhanced Liver Fibrosis (ELF) test with semaglutide treatment. • Novo Nordisk plans to file for regulatory approvals in the US in the first half of 2025, marking a step towards a new treatment option.